A Phase 3 interventional study of IMN and Placebo in Prolonged Pregnancy and Nulliparity, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to determine whether cervical ripening with isosorbide mononitrate reduce caesarean section in women with post term pregnancies.
The purpose of this trial is to determine whether cervical ripening with 40 mg of isosorbide mononitrate given intravaginally at 41+0, 41+2 and 41+4 weeks reduce cesarean section in nullipara with post term pregnancies. Treatments will be administered by midwifes in the maternity wards, women will be allowed to go back home in case of Bishop score\<6. Otherwise labor will be induced with oxytocin. If undelivered at 41+5, women with Bishop score\<6 will be induced with prostaglandins according to local protocols.
30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.
This study's enrollment of 1,409 is above the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.
Browse Pregnancy, Prolonged studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isosorbide mononitrate
Drug: IMN
Administration of placebo of IMN
Drug: Placebo
Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
Number of cesarean sections
Time frame: 10 days
Number of labor inductions
Time frame: 10 days
Number of spontaneous labors
Time frame: 10 days
Cesarean for failed labor induction
Time frame: 10 days
Cesarean for FHR abnormalities
Time frame: 10 days
Cesarean for arrested labor
Time frame: 10 days
Mean time between randomisation and spontaneous labor
Time frame: 10 days
Isosorbide mononitrate adverse effects
Time frame: 10 days
Maternal satisfaction
Time frame: 10 days
Neonatal morbidity
Time frame: 10 days
Mean time between randomisation and delivery
Time frame: 10 days
Mean duration of labor
Time frame: 10 days
The record gives a start of Jun 2009, a primary completion of Dec 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →